Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Table 2 Changes in other asthma medications post omalizumab therapy

Duration >120 days	Baseline^a	Follow-up^b	p-value^c
N = 158	N (%)	N (%)	p-value^c
ICS			<0.001*
With ICS	158 (100.0 %)	138 (87.3 %)
Without ICS	0 (0.0 %)	20 (12.7 %)
ICS + LABA			<0.001*
With ICS + LABA	157 (99.4 %)	124 (78.5 %)
Without ICS + LABA	1 (0.6 %)	34 (21.5 %)
OCS			<0.001*
With OCS	146 (92.4 %)	91 (57.6 %)
Without OCS	12 (7.6 %)	67 (42.4 %)
SAMA			<0.001*
With SAMA	49 (31.0 %)	4 (2.5 %)
Without SAMA	109 (69.0 %)	154 (97.5 %)
LAMA			0.027*
With LAMA	27 (17.1 %)	13 (8.2 %)
Without LAMA	131 (82.9 %)	145 (91.8 %)

^aBaseline: 1 year before the index date
^bFollow-up: 2 months before discontinuation (discontinuation of therapy was defined as a gap in therapy of 56 days)
^cFisher’s exact test, *P < 0.05